You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Developing Novel Antibiotics Against Yersinia pestis

    SBC: NOVOBIOTIC PHARMACEUTICALS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop broad-spectrum antibiotics against Yersinia pestis and other important human pathogens. The potential use of engineered, multi-drug-resistant strains as agents of bioterrorism necessitates the development of new anti-Y. pestis therapies. This is a challenging goal, since the last novel class of broad-spectrum antib ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid Clinical Surge-Testing for Biothreat Agents

    SBC: FIRST LIGHT BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Following a bioterrorist attack, hundreds of thousands of potential victims may require testing and treatment. The critical need to test large numbers of people for exposure to a biothreat agent may overwhelm the capacity of the clinical and public health infrastructure. The approximately 25,000 sentinel laboratories in the Laboratory Response Network, which co ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an anti-malaria toxin vaccine candidate

    SBC: ANCORA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Malarial disease represents one of the most pressing medical healthcare issues facing the world today. While limited drug treatment options exist, a vaccine solution is widely considered as one of the most effective therapeutic weapons to combat malaria. Despite years of research, though, malarial vaccine initiatives have yet to produce a viable candidate. One ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  4. Discovery of B. pseudomallei therapeutics for Biodefense

    SBC: MICROBIOTIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Burkholderia pseudomallei is a bioterrorist threat. With the best current therapies, lethality is typically as high as 40%. The overall goal of this proposal is the development of new drugs against this organism. In Phase I, the high sequence similarity between 8. pseudomallei and its less virulent relative Pseudomonas aeruginosa was exploited to build innovati ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  5. High Field Magnets for MRI Applications

    SBC: Supercon, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The specific aim of the Phase I and Phase II research program will be to design and build an "open", split pair coil, high field (>1 .5T), cryogen-free MRI magnet. The key innovation that will make this goal feasible is the development of an advanced, high performance, round high temperature superconductor capable of operation at 20 Kelvin. Operating at a te ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Vector Identification and Gene Delivery Approach in Pigs

    SBC: GWATHMEY, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Heart failure (HF) represents an enormous clinical problem demanding effective therapeutic approaches. Despite advances in traditional approaches to its treatment, including pharmacological management, myocardial revascularization, mechanical assist devices, and transplantation, heart failure remains a leading cause of death worldwide. Therefore, a novel therap ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Spectral imaging for automated malignant blast counting

    SBC: CAMBRIDGE RESEARCH AND INSTRUMENTATION            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to extend our successful development of an agile spectral light source for light microscopy, funded through the NCI-IMAT initiative, into FDA trials. The SpectraLamp(tm) device enables the automated and quantitative analysis of double-immunostained samples in brightfield (non-fluorescence-based) microscopy, with particular utility for hematopatho ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Puerarin to Reduce Alcohol Drinking

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This application is a resubmission in response to AA-04-002 from the National Institute on Alcohol Abuse and Alcoholism to continue our STTR (Phase I and II) study on the development of NPI-031G (Puerarin), an Isoflavone-C-glycoside isolated from Puerira lobota (Kudzu), as a botanical anti-craving agent for the treatment of alcohol drinking problems. In STTR ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  9. Clinical Development a Therapeutic Agent for COPD

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: N/A

    Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases, including chronic pulmonary disease (COPD), asthma, cystic fibrosis, and bronchiectasis. Despite the obvious medical importance, there presently are no effective therapies to control excess mucus secretion in these diseases, and very few potential therapeutic targets. We discovered that a ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Saline Enhanced Radiofrequency Ablation for Liver Tumors

    SBC: E.P., LTD            Topic: N/A

    DESCRIPTION (provided by applicant): Liver cancer is a significant and increasing health concern. In the United States, there will be over 72,500 cases of colorectal cancer metastasized to the liver. Hepatocellular carcinoma (HCC) is also an increasing concern in the United States, primarily due to a rise in hepatitis C. The incidence of HCC in the United States has doubled to 17,550 cases over th ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government